ALS risk but not phenotype is affected by ataxin-2 intermediate length polyglutamine expansion
Citation Manager Formats
Make Comment
See Comments
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
TDP-43 is the major disease protein in amyotrophic lateral sclerosis (ALS).1 Recently, ataxin-2, a polyglutamine (polyQ) protein mutated in spinocerebellar ataxia type 2 (SCA2),2 has been shown to interfere with TDP-43 toxicity in ALS animal models and to abnormally localize in ALS spinal cord neurons.3 An increased risk for ALS and an earlier age at disease onset were observed in patients with an intermediate-length CAG expansion (24–33) [(CAG)24–33] in ataxin-2 encoding gene (ATXN2).
To test the hypothesis that ATXN2 (CAG)24–33 expansion is a clinical modifier in ALS, we determined the length of the polyQ expansion in 247 patients with ALS and correlated clinical phenotype in the (CAG)24–33 expansion patients with those with a CAG expansion below 24 repeats.
Methods.
Considered in the present study were patients with ALS according to the El Escorial criteria4 evaluated at the ALS Clinic of Padova from January 2004 to August 2010. Patient data entered included sex, age and site of onset (bulbar or spinal), disease duration at ALS diagnosis, forced vital capacity (FVC, expressed as percentage of the expected value) at first assessment, survival defined as the time from onset to …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Sevil Yaşar and Dr. Behnam Sabayan
► Watch
Related Articles
- No related articles found.
Topics Discussed
Alert Me
Recommended articles
-
Articles
Expanded ATXN2 CAG repeat size in ALS identifies genetic overlap between ALS and SCA2P. Van Damme, J.H. Veldink, M. van Blitterswijk et al.Neurology, May 11, 2011 -
Article
Ataxin-1 and ataxin-2 intermediate-length PolyQ expansions in amyotrophic lateral sclerosisFrancesca L. Conforti, Rossella Spataro, William Sproviero et al.Neurology, November 28, 2012 -
Article
Screening for novel hexanucleotide repeat expansions at ALS- and FTD-associated lociFang He, Julie M. Jones, Claudia Figueroa-Romero et al.Neurology Genetics, May 11, 2016 -
Special Article
Degenerative ataxias, from genes to therapiesThe 2015 Cotzias LectureStefan M. Pulst et al.Neurology, June 13, 2016